Vevoctadekin

**Semantic type:** Pharmacologic Substance

**Definition:** An engineered variant of the human cytokine interleukin-18 (IL-18; IL18), with potential immunostimulating and antineoplastic activities. Upon administration of vevoctadekin, the IL-18 variant binds to and activates the IL-18 receptor. This promotes T-cell persistence and enhances the activity and maturation of natural killer (NK) cells, which potentiates the immune response against tumor cells. The IL-18 variant is engineered to preferably bind to the IL-18 receptor and not IL-18 binding protein (IL-18BP), which acts as a decoy receptor of IL-18 and prevents the activation of IL-18 receptor in the tumor microenvironment (TME).

**Synonyms:** - Engineered IL-18 Variant ST-067 - Engineered Interleukin-18 Variant ST-067 - ST 067 - ST-067 - ST067 - VEVOCTADEKIN